Classes of Myeloma Drugs Overview
Immunomodulatory Agents (IMiDs)
Proteasome Inhibitors (PI's)
Thalidomide (Thalomid®)
Bortezomib (Velcade®)
Monoclonal Antibodies (mAbs)
Daratumumab (Darzalex® and Darzalex Faspro®) Target: CD38
Cytotoxic/ Steroids XPO1 Inhibitors
Melphalan (Alkeran®)
Lenalidomide (Revlimid®)
Carfilzomib (Kyprolis®)
Pomalidomide (Pomalyst®)
Ixazomib (Ninlaro®)
Elotuzumab (Empliciti®) Target: SLAM F7
Cyclophosphamide (Cytoxan®)
Selinexor (Xpovio®)
MOA: XPO1 Inhibitor
Antibody Drug Conjugate (ADC) CELMoDs
Belantamab mafodotin (Blenrep®)* Target: BCMA
CAR (Chimeric Antigen Receptor) TCell Therapy
Mezigdomide
Idecaptagene vicleucel (ABECMA®) Target: BCMA
Iberdomide* *Not yet approved in myeloma
Ciltacaptagene autoleucel (CARVYKTI® ) Target: BCMA
Isatuximab (Sarclisa® ) Target: CD38
Bendamustine (Treanda®)
Steroids:
Dexamethasone (Decadron®) Prednisone (Deltasone®)
Teclistamab (TECVAYLI®) Target: BCMA
Talquetamab (TALVEY®) Target: GPRC5D
Elranatamab (ELREXFIO™) Target: BCMA
Linvoseltamab (LYNOZYFIC™ ) Target: BCMA CD3
Cevostamab* Target: FcRH5 *Not yet approved in myelomma
Bispecific Antibodies (BiSAb) Other Supportive Care
Venetoclax (Venclexta®)* for t(11;14) *Not yet approved in myeloma Bone strengthener: Pamidronate (Aredia®) Zoledronate (Zometa®) Denosumab (Xgeva®)
Infection Prevention: Acyclovir, Valacyclovir; Levofloxacin
Infection Prevention: SMX-TMP or sulfamethoxazoletrimethoprim
Infection Prevention: IVIG, or intravenous immunogloulin
